GICS Sector : Healthcare
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States.Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria.The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Synlogic Reports Third Quarter 2024 Financial Results
Nov -12
Synlogic Reports Second Quarter 2024 Financial Results
Aug -08
The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits
May -23
Synlogic Reports First Quarter 2024 Financial Results
May -14
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Mar -19
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Mar -19
Synlogic Adopts Limited Duration Stockholders Rights Plan
Feb -20
Why Is Synlogic (SYBX) Stock Down 55% Today?
Feb -09
Synlogic's Synthetic Biology Therapeutics segment growth is driven by increasing adoption of microbiome-based therapies, strong pipeline of novel candidates, and partnerships with pharmaceutical companies. The company's proprietary platform enables precise gene regulation, enhancing treatment outcomes. Growing demand for innovative therapies in oncology and rare genetic disorders also contributes to the segment's 14.43% growth.
An investigational Synthetic Biotic medicine designed to treat phenylketonuria (PKU), a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine.
An investigational Synthetic Biotic medicine designed to treat homocystinuria, a rare genetic disorder that affects the body's ability to break down the amino acid methionine.
An investigational Synthetic Biotic medicine designed to treat gout, a type of inflammatory arthritis that occurs when there is too much uric acid in the blood.
An investigational Synthetic Biotic medicine designed to treat inflammatory bowel disease (IBD), a chronic condition characterized by inflammation in the digestive tract.
Synlogic, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for certain diseases.
Synlogic, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers.
Synlogic, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials.
Synlogic, Inc. has a high threat of new entrants due to the growing demand for microbiome-based therapies.
Synlogic, Inc. operates in a highly competitive industry with multiple players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 28.83% |
| Debt Cost | 3.95% |
| Equity Weight | 71.17% |
| Equity Cost | 9.09% |
| WACC | 7.60% |
| Leverage | 40.50% |
Value: 8.2
Growth: 8.6
Quality: 6.4
Yield: 0.0
Momentum: 10.0
Volatility: 3.0
1-Year Total Return ->
Value: 7.2
Growth: 5.6
Quality: 4.8
Yield: 0.0
Momentum: 8.5
Volatility: 2.7
1-Year Total Return ->
Value: 9.2
Growth: 4.8
Quality: 5.8
Yield: 0.0
Momentum: 0.0
Volatility: 0.3
1-Year Total Return ->
Value: 6.0
Growth: 4.2
Quality: 3.6
Yield: 0.0
Momentum: 4.5
Volatility: 0.7
1-Year Total Return ->
Value: 8.8
Growth: 1.2
Quality: 6.9
Yield: 0.0
Momentum: 1.5
Volatility: 0.3
1-Year Total Return ->
Value: 7.2
Growth: 1.2
Quality: 3.9
Yield: 0.0
Momentum: 4.0
Volatility: 0.3
1-Year Total Return ->